Highly accurate in-vitro practices are becoming absolutely vital as is looking at cost-effective assay development. Cell based assays now play an important role into the research pipeline, making a large percentage of total research time and is set to show considerable growth over the coming years.There are currently 15 FDA approved kinase inhibitor drugs, but there currently remains a huge uncapped potential with these drugs as over 90% of the kinome is unknown. Novel assays have identified kinase targets, improved the function of kinase inhibitors and led to an acceleration in drug discovery with new inhibitor classes.See at Cell Based Assays 2013 how HCA can be utilised in your pre-clinical toxicology procedures to give highly accurate data.WHY ATTEND THIS EVENT: Hear the latest on Phenotypic screening; how target based screening is allowing for identification of small moleculesSee how you can implement a primary cell assay plan through a case study of SARdriving assayThe latest in GPCR and other ion channel targeting pathways and how they are being used in the most recent drug discovery assaysAdopt accelerated primary cell screening systems such as those utilised by GSK